INTRODUCTION
Aripiprazole is a novel antipsychotic drug that has a different pharmacological profile from typical and atypical antipsychotics. It is also a n e w g e n e r a t i o n , d o p a m i n e -b a l a n c i n g antipsychotic drug, which is a partial agonist for dopamine D 2 and D 3 , serotonin 5-HT 1A , 5-HT 2C and 5-HT 7 receptors, and antagonist for 5-HT 2A and 5-HT 6 receptors [1] [2] [3] [4] . It is considered that partial D 2 agonism stabilizes dopaminergic nerve communication in the mesolimbic and m e s o c o r t i c a l p a t h w a y s 5 . T h e e f f e c t o f aripiprazole resulting in 5-HT 2A receptor blockade and 5-HT 1A receptor stimulation increases dopamine release 6 . Evidence from human and animal studies suggests that dopamine plays a critical role in the pathophysiology of depression 7, 8 and the therapeutic efficacy of antidepressants 9, 10 . The fact that patients with Parkinson's disease, whose dopaminergic systems have significantly degenerated, are affected by a high incidence of depression (40%) supports the suggestion that dopaminergic system impairment exists in depression 11, 14 . There is evidence of basal ganglia dysfunction from imaging studies of major depressive disorders 15 . Dopamine plays an important role in basal ganglia function. In studies performed with magnetic resonance imaging (MRI) the signal density of the basal ganglia of depressive patients was found to be higher compared to healthy individuals 16 . In addition, studies with computerized tomography and MRI have revealed a reduced basal ganglia volume in these patients 17, 18 . In studies with SPECT, low regional blood flow was found in the basal ganglia of depressive patients, while reduced glucose metabolism in the area was showed with PET 19 . To support this hypothesis, studies which measured homovanilic acid(a metabolite of dopamine) concentrations in cerebrospinal fluid (CSF) of patients with major depression found it to be reduced 8, 20 . In postmortem brain analyses of depression patients who committed suicide, a reduction in the dopamine metabolite, hydroxyphenyl acetic acid, has been reported. These studies support the dopamine abnormality theory of depression 21 . Aripiprazole has been used in manic and mixed episodes of bipolar disorder and has been found to be effective in this field after being approved for schizophrenia treatment in 2002. Studies have revealed that aripiprazole is effective in schizophrenia, major depressive disorder and manic, depressive and protective treatment of bipolar disorder 22, 23 . It has been shown in several studies that aripiprazole is effective as an augmentation therapy in resistant depression and as add-on therapy in the treatment of major depressive disorder 24, 25 . Although human studies have revealed that antipsychotics are effective in depression, especially when a psychotic component is present, recent studies have indicated that successful antidepressant activity is achieved by aripiprazole in depressive patients without a psychotic component who have had insufficient response to other medications 26, 27 . In patients with bipolar disorder who were unresponsive to mood stabilizers, aripiprazole was demonstrated to have an antidepressant effect. In metaanalyses of two placebo controlled trials evaluating the efficacy of aripiprazole as monotherapy in bipolar depression, aripiprazole was found to be superior to placebo in the1st and 6 th weeks but no difference was detected in week 8 28 . It has been reported that aripiprazole has s h o w n a n t i d e p r e s s a n t e f f i c a c y w h e n administered alone to animals 29 . In animal studies, aripiprazole was found out to enhance antidepressant activity when administered with antidepressants except for bupropion and desipramine 30 . In this study, it is considered that aripiprazole is a dopamine system regulator that should be efficacious in depression treatment. Its effects on the dopaminergic system play a crucial role and thus we aimed to investigate aripiprazole's efficacy in rats.
MATERIALS AND METHODS

Materials
Experimental Animals
In this study 32 male Wistar Albino rats with a weight of 200±15 g were used. The rats were adapted to the environment one week prior to the experiment. The rats were kept in separate plastic cages with beds. They could reach standard rat food and tap water. To get accustomed to the taste of sucrose, they were provided with sucrose (1%) for one week before the procedure. Cage temperature was held at 22±2ºC. The light-dark cycle was established as twelve hours of daylight and 12 hours of darkness by switching the lights on at 06:00 am and off at 06:00 pm.
The rats were assigned to 4 groups of eight. Aripiprazole and escitalopram was administered orally diluted in saline. The first group (n=8) was the control group and saline (in an equivalent amount given orally) was used without Chronic Mild Stress (CMS). For the second group (n=8), aripiprazole (2.5 mg/kg) was administered with CMS; for the third group (n=8), escitalopram (10 mg/kg) was administered with CMS and for the fourth group (n=8) (the depression group) saline with CMS was administered. The rats were housed individually. Homogeneous distribution among the groups was provided. The study was performed in accordance with the Helsinki Declaration and Animal Experiments Ethical Committees' Study Methods and Principles Regulations published in the official gazette number 26220 on 6 July 2006 by the Turkish Government Ministry of Forestry and Water Affairs.
Chronic Mild Stress Model
The chronic mild stress (CMS) model is a wellvalidated rat model of core depressive symptoms 31, 32 . In this model, the rats are continuously exposed to various types of relatively mild stress. These stressors include leaving the rats without water and then putting an empty water bottle into the cage, lighting the cage continuously, sloping the cage, separating the cages, making the floor of the cage wet with 300cc water, implementing a 90 db noise and switching the lights on and off at 300 times a minute. These stressors are applied for several hours alternately and lasted for weeks or months 31 . The applied procedures of CMS may be seen in Table 1 .
Sucrose Consumption Test
The sucrose consumption test was applied to rats before the CMS started. The sucrose test is used to measure anhedonia which is described as the decrease in sucrose consumption when compared to control and starting values. Sucrose consumption in an hour after 20 hours of hunger was investigated at the begining. The results were recorded as basal values. All results were calculated in mililiters. The sucrose consumption test was repeated on the fourth day of each week at 12:00 pm for four weeks and the results were recorded. The CMS phase was then held. This process was repeated for four weeks 33 .
Statistical Analyses
Statistical analyses were performed using the "SPSS 13.0 for Windows" pocket program. Intergroup differences were investigated with the Kruskal-Wallis test of variance analysis. Two groups' comparisons were performed by the Mann-Whitney U test. P values under 0.05 were accepted to be significant.
RESULTS
Sucrose Consumption Test Results
In our study, the rats' sucrose consumption at the beginning and after the first week was not different among the groups. The sucrose consumption of the group where CMS was applied was significantly lower in the second, third and fourth weeks compared to the control group. In the aripiprazole administered group, sucrose consumption values were not different in the first and second weeks while they were significantly higher in the 3 rd and 4 th weeks compared to the CMS group. In the aripiprazole group sucrose consumption was not different from the control group for the entire time. In the escitalopram group, sucrose consumption values were not different at the beginning or in the first and second weeks but they were significantly higher in the third and fourth weeks compared to CMS group. Also in the escitalopram group sucrose consumption was not different from the control group for the whole study.
When the sucrose consumption values of the aripiprazole and escitalopram groups were compared, no difference was detected for the entire study period. Sucrose consumption test results before and during the study are shown in Table 2 .
Water consumption in the course of the sucrose consumption test did not differ among the groups at the beginning, in the first, second, third and fourth weeks. In the fourth week, water consumption in the aripiprazole group was found to be significantly higher compared to the control group. All groups' water consumption values during the study are available in Table 3 . Groups' weights were not different in the whole experiment period. Weight changes are also presented in Table 4 .
DISCUSSION
The aripiprazole group's sucrose consumption values were significantly higher in the third and fourth weeks compared to the CMS group and sucrose consumption was not different from the control group during the entire study, indicating that aripiprazole was efficient in preventing depression and has a similar antidepressant effect as escitalopram, which is used in clinical practice as an efficient antidepressant 34 . In experimental studies with different depression models, aripiprazole has been found to have antidepressant effects in rats 29, 30 . Burada et al. found that 6 mg/kg aripiprazole treatment decreased immobility time in rats. In the same study they used the forced swimming test 29 . In this study, a single dose did not reduce immobility time in rats, however chronic administration of 7 and 14 days was successful in reducing this period. In another study in which aripiprazole was administered with other antidepressant medications, it was found to enhance the efficacy of other drugs in the forced swimming test 30 . However in another study in which rats were evaluated by the tail suspension test, aripiprazole monotherapy did not change the immobility time. In this study it was also shown that aripiprazole decreased the immobility time when administered with fluoxetine 35 . Many depression models have been described for rats. In our study the CMS model was used which is a well-validated rat model. Our study is the first one, which has investigated aripiprazole's efficacy with the CMS model. Additionally, the sucrose consumption test is considered as the best match of anhedonia in animals which is a good predictor of human depression 37, 38 . Clinical trials of aripiprazole have revealed that it is effective in resistant depression, bipolar depression and major depression. In nonpsychotic depression treatment, it has not been found to be effective as monotherapy 39 . It is also known that dopamine activity in the frontal cortical area is impaired in depression 8 . Preclinic data supports that aripiprazole may be effective in depression treatment through partial dopamine agonism and 5-HT antagonism [40] [41] [42] [43] . In studies with animal depression models, depression was shown to be related to dopaminergic deficiency and this condition may be reversed by dopamine agonists 8 . Aripiprazole, a partial dopamine agonist may play a dopamine balancing role by enhancing dopamine's effect at frontal sites and supressing its excessive activity in subcortical sites 44 . In animal studies, the mesolimbic dopaminergic system, especially the nucleus accumbens was found to manage pleasure behavior that conceives reward 8, 45, 46 . In the brain reward system, food, sexual intercourse and drug abuse are the behaviors resulting in dopamine release. Animal studies have revealed that these behaviors were interrupted in depression 47 .
Evidence from previous studies shows that antidepressant drugs have and explicit effect on the dopaminergic system 48 . In experimental analyses, long term administration of various antidepressants has been found to enhance D 2 receptor activity 45 . Amplified dopaminergic neurotransmission was considered to contribute to this therapeutic effects 9 . Data from postmortem human studies and studies with PET an SPECT have revealed a decrease in D 2 and D 3 receptor expression in depresssion and an increase in dopamine release with antidepressant treatment 49 . The serotonergic system is considered to regulate mood, sleep, sexual function, impulse control and eating behavior (50). 5-HT 1A , 5-HT 2A and 5-HT 2C receptors are known to play a role in depression and it is also known that a serotonin increase in prefrontal cortex cures depression 51 . The serotonergic system plays a crucial role in the effects of antidepressants 52 . Studies suggest increases in neurotransmission at postsynaptic 5-HT 1A receptors may mediate the therapeutic effects of different classes of antidepressant drugs including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRI) and monoamine oxidase inhibitors (MAOI) 53 . In treatment with SSRIs, the downregulation developed by 5-HT 1A receptor agonism is considered to be the best indicator of efficacy 54 . In addition, many antidepressants with proven efficacy are 5-HT 2C antagonists and reduce 5-HT 2 receptor affinity after several applications 55 . 5-HT 2C antagonists also enhance their effect when administered with antidepressants. In animal studies 5-HT 2A antagonists were proved to have an antidepressant effect 56 . Aripiprazole when administered as an additional treatment in depression is claimed to be influential with its strong partial agonism of D 2 , D 3 and 5-HT 1A receptors and antagonism of 5-HT 2 43,57,58 . In these studies aripiprazole was indicated to increase firing rate of 5-HT neurons. 5-HT 2C receptors inhibit dopamine and noradrenaline release at the ventral tegmental site. This leads to disinhibition of dopamine and n o r a d r e n a l i n e a n d m a y m e d i a t e t h e antidepressant and anxiolytic effects of aripiprazole 59 . This finding has indicated that the antidepressant effect of aripiprazole may be through its partial agonism of D 2 , D 3 , 5-HT 1A and 5-HT 2C receptors and antagonism ofn 5-HT 2A .
In conclusion, our study indicates that aripiprazole has an antidepressant effect in rats. Aripiprazole, with its proven efficacy, should be investigated in human studies in order to determine its effect in major depression as a monotherapy.
